phone Contact Us

Company Updates / Tech Announcement

Opharmic Launches MeticStim® Platform for Non-Invasive Ultrasound Cell Stimulation

MeticStim® Platform for Non-Invasive Ultrasound Cell Stimulation

Hong Kong, 15 February 2021

Opharmic Technology (HK) Limited is proud to announce the official launch of MeticStim®, its proprietary platform for precise, non-invasive ultrasound-mediated cell stimulation.

The new MeticStim® platform complements MeticTouch® (focused on drug delivery) by offering targeted acoustic energy to modulate cellular behavior safely and effectively, without the need for chemical agents or invasive procedures.

MeticStim® leverages advanced ultrasound technology to deliver controlled mechanical stimulation to cells, enabling potential applications across multiple therapeutic areas. Initial focus areas include regenerative medicine, optimization of cell-based therapies (such as enhancing CAR-T cell performance), and potential uses in ophthalmology for conditions like myopia management. This non-invasive approach has the potential to improve cell proliferation, differentiation, and functionality while maintaining high safety profiles.

Since its establishment, Opharmic has invested significant R&D efforts into refining ultrasound transducer design and biological response characterization. The launch of MeticStim® represents a key milestone in the company’s mission to develop versatile, patient-centric platforms that address unmet medical needs through gentle, precise energy delivery.

“This launch of MeticStim® marks an exciting expansion of our ultrasound technology capabilities,” said Dr. Langston Suen, CEO of Opharmic Technology. “By harnessing the power of focused ultrasound for cell stimulation, we are opening new possibilities in regenerative medicine and beyond. As a non-drug platform, MeticStim® perfectly complements our MeticTouch® platform, reinforcing Opharmic’s position at the forefront of ultrasound medtech innovation.”

The MeticStim® platform is currently advancing through in-vitro and preclinical studies, with early data showing promising results in cellular modulation. Opharmic plans to pursue strategic collaborations and further regulatory development to bring these benefits to clinical applications.

This announcement underscores Opharmic’s commitment to building a robust pipeline of ultrasound-based solutions that prioritize patient comfort, accessibility, and therapeutic efficacy. As the company progresses, MeticStim® will play a vital role in its long-term vision of transforming treatment paradigms in ophthalmology, oncology, and regenerative medicine.

Author

Opharmic Technology